Bio-Stride Financial Model

Comprehensive Cash Flow Projections & Unit Economics

Lifetime Value (LTV)
₹10.5L
Per hospital customer over 5 years
Customer Acquisition Cost (CAC)
₹75K
Blended across all channels
LTV:CAC Ratio
14:1
Industry benchmark: 3:1
Gross Margin (Blended)
72%
Device: 65% | Consumables: 78%
Payback Period
8 months
From first device sale
Break-even Timeline
Q3 2027
24 months post-launch
Base Case
Conservative
Optimistic

Revenue Projections (2025-2030)

Cumulative Cash Flow Analysis

Unit Economics Breakdown

Product Line Unit Price (₹) COGS (₹) Gross Profit (₹) Gross Margin % Annual Volume Annual GP (₹ Cr)
TBI Analyzer Device 175,000 61,250 113,750 65% 1,200 13.65
Test Cartridges 400 88 312 78% 240,000 7.49
SaaS Analytics 50,000/yr 5,000 45,000 90% 800 3.60

Monthly Cash Flow Projections (First 12 Months)

Month Revenue (₹ L) COGS (₹ L) OpEx (₹ L) EBITDA (₹ L) Cash Balance (₹ L) Burn Rate

Key Financial Assumptions

Market Penetration Rate
0.5% Year 1 → 4.5% Year 5
Device ASP Growth
5% annually (economies of scale)
Consumables Attach Rate
200 tests/device/month
Customer Retention
92% annual retention
R&D Investment
20% of revenue
Working Capital Cycle
60 days receivables, 45 days payables

Investor-Specific Metrics

Metric 2025 2026 2027 2028 2029 2030
Revenue (₹ Cr) 0.5 8.2 45.6 128.4 245.8 398.5
YoY Growth % - 1540% 456% 182% 91% 62%
Gross Profit (₹ Cr) 0.3 5.9 32.8 92.4 177.0 286.9
EBITDA Margin % -120% -45% 15% 28% 35% 38%
Cash Flow (₹ Cr) -0.8 -4.2 5.8 32.1 78.4 142.3
Cumulative CF (₹ Cr) -0.8 -5.0 0.8 32.9 111.3 253.6
Download Full Financial Model (Excel)